Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3992229 | Journal of Thoracic Oncology | 2007 | 7 Pages |
Abstract
The vast majority of octogenarian patients with NSCLC receive antineoplastic therapy, but only one third of this population receives stage-specific GRT. Although many patients choose aggressive therapies, a small but clinically significant portion chose not to receive the offered GRT. More data are needed on appropriate therapy recommendations for this patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Geoffrey R. MD, Panos MD, Alona MA, Lecia V. MD, MPH,